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Abstract
Introduction: Previous meta-analyses of magnesium sulphate infusion in the treatment of aneurysmal
subarachnoid hemorrhage (SAH) have become outdated due to recently published clinical trials. Our aim was thus
to perform an up-to-date systemic review and meta-analysis of published data on the use of magnesium sulphate
infusion in aneurysmal SAH patients.
Methods: A systemic review and meta-analysis of the literature was carried out on published randomized
controlled clinical trials that investigated the efficacy of magnesium sulphate infusion in aneurysmal SAH patients.
The results were analyzed with regard to delayed cerebral ischemia (DCI), delayed cerebral infarction, and favorable
neurological outcomes at three and six months. The risks of bias were assessed using the Jadad criteria, with a
Jadad score >3 indicating a lower such risk. Meta-analyses are presented in terms of relative risk (RR) with 95%
confidence intervals (CIs).
Results: Six eligible studies with 875 patients were reviewed. The pooled RR for DCI was 0.87 (95% CI, 0.36 to 2.09;
P = 0.75). That for delayed cerebral infarction was 0.58 (95% CI, 0.35 to 0.97; P = 0.04), although this result did not
persist if only randomized clinical trials with a lower risk of bias were included (RR 0.61, 95% CI, 0.31 to 1.22; P =
0.17). The pooled RR for a favorable outcome at three months was 1.14 (95% CI, 0.99 to 1.31; P = 0.07), and that for
a favorable outcome at six months was 1.08 (95% CI, 0.94 to 1.24; P = 0.29).
Conclusions: The present findings do not lend support to a beneficial effect of magnesium sulphate infusion on
delayed cerebral infarction. The reduction in DCI and improvement in the clinical outcomes of aneurysmal SAH
patients following magnesium sulphate infusion observed in previous pilot studies are not confirmed, although a
beneficial effect cannot be ruled out because of sample size limitation.
Introduction
Although spontaneous subarachnoid hemorrhage (SAH)
accounts for only 3 to 5% of all strokes and 4.4% of
deaths from stroke [1,2], the relative youth of the indivi-
duals affected means that it is actually responsible for
approximately 25% of all years of life lost as a result of
stroke [3]. Such complications as early brain injury and
delayed ischemic neurological deficits remain a major
cause of morbidity and mortality in this group of
patients.
Pilot clinical trials using magnesium sulphate in
patients with acute aneurysmal SAH have reported a
trend toward a reduction in clinical deterioration due to
delayed cerebral ischemia (DCI) and an improvement in
clinical outcomes [4-11], although two recently com-
pleted clinical trials failed to demonstrate any improve-
ment in neurological outcomes [12,13]. Interestingly,
however, a German trial found a significant decrease in
delayed cerebral infarction but no improvement in neu-
rological outcomes, in contrast to other retrospective
analyses [13-15].
Previous meta-analyses of the use of magnesium sul-
phate infusion to treat aneurysmal SAH have become
outdated due to recently published clinical trials [16-18].
Hence, we conducted an up-to-date literature review
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and meta-analysis of published data on patients with




We included only randomized controlled clinical trials
comparing magnesium sulphate infusion to placebo
infusion for patients with acute aneurysmal SAH.
Types of outcome measures
The primary outcome was dichotomized neurological
outcome using Glasgow Outcome Scale (GOS) [19] and
modified Rankin Scale (mRS) [20] at three and six
months. We also assessed surrogate outcome with DCI
and delayed cerebral infarction according to a recent
consensus paper [15].
Definition of outcome measures
In our systemic review and meta-analysis, DCI was
defined as the occurrence of: clinical deterioration,
which was manifested clinically as a new focal neurolo-
gical deficit (motor or speech deficit) that developed
after SAH or a decrease in the Glasgow Coma Scale of
two or more points for more than six hours; and/or
delayed cerebral infarction, which was defined as a new
cerebral infarction within three weeks that was not
related to post-treatment (coiling or clipping) complica-
tions, the ventricular catheter track, a rebleed, or hydro-
cephalus [15].
Another outcome, delayed cerebral infarction, was
similarly defined as a new cerebral infarction within
three weeks that was not related to post-treatment (coil-
ing or clipping) complications, the ventricular catheter
track, a rebleed, or hydrocephalus.
Neurological outcomes were defined by the GOS [19]
and mRS [20]. A favorable outcome was defined as a
GOS score of 4 to 5 or a mRS score of 0 to 2.
Search strategy
Cochrane Central Register of Controlled Trials (Clinical
Trials), EMBASE, PubMed, and Ovid MEDLINE
searches (using the keywords magnesium AND subar-
achnoid hemorrhage) of studies employing randomized
controlled trials and published between 1 January, 1980
and 15 June, 2010 were carried out. The references
listed in these publications were also searched for rele-
vant studies.
Risk of bias assessment
The Jadad criteria were used to assess the risk of bias
[21]. The criteria included randomization, blinding, and
an explanation of withdrawal or loss to follow up. Clini-
cal trials with Jadad scores of 3 or above were
considered to be of high quality. No funnel plot was
employed to test for asymmetry, because fewer than 10
clinical trials were ultimately included.
Statistical analysis
Statistical analyses were generated using SPSS for Win-
dows Version 15.0 (SPSS Inc., Chicago, Illinois, USA)
and Review Manager 5 (Cochrane Collaboration, Oxford,
UK). Statistical significance was taken as a P value less
than 0.05 or a 95% confidence interval (CI) of relative
risk (RR) not including 1. Data are represented using
numbers (percentages) for the categorical variables and
mean +/- standard deviations for the numerical variables.
The I2 value for heterogeneity describes the proportion
of total variation in a study estimated to be due to het-
erogeneity. The random-effects model was employed to
pool studies when statistical heterogeneity occurred (the
P value was less than 0.1) or when the I2 value was larger
than 0.3; otherwise, the fixed-effects model was used.
Results are presented using the RRs and 95% CIs.
Results
Search results
A PubMed literature search (using the keywords magne-
sium AND subarachnoid hemorrhage) of studies
employing randomized controlled trials and published
between 1 January, 1980 and 15 June, 2010 yielded 20
publications. Additional searches of the Cochrane Cen-
tral Register of Controlled Trials (Clinical Trials),
EMBASE, and Ovid MEDLINE (using the keywords
magnesium AND subarachnoid hemorrhage and consid-
ering only human studies) yielded 51, 72, and 91 publi-
cations, respectively. The references listed in these
publications were also searched for relevant studies.
Examination of the abstracts and/or manuscripts
revealed seven completed randomized controlled clinical
trials on the use of magnesium in patients with aneurys-
mal SAH [6,8-13] and one methodology-only abstract
[22]. None of these studies detected a statistically signifi-
cant improvement in primary clinical outcome
measures.
Study descriptions
Veyna and colleagues [6] reported the results of a
40-patient prospective single-blinded clinical trial of
high-dose magnesium sulphate infusion therapy (a bolus
of 6 g followed by 2 g per hour intravenous infusion,
with a target magnesium level of 4 to 5.5 mg/dl) follow-
ing spontaneous SAH. They enrolled patients with Hunt
and Hess grades II to IV at admission and presenting
within 72 hours after spontaneous SAH. In the magne-
sium treatment group, they maintained the magnesium
sulphate infusion for 10 days. They presented no data
on DCI or delayed cerebral infarction. A favorable
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outcome (good recovery or moderate disability, as
defined by GOS 4 to 5) was achieved in 13 of 20 (65%)
patients receiving magnesium sulphate infusion and 10
of 20 (50%) patients receiving the placebo treatment. No
data were available for excellent outcome (good recov-
ery, as defined by GOS 5 or mRS 0 to 1).
Van den Bergh and colleagues [8] reported the magne-
sium group results for the Magnesium and Acetylsalicylic
Acid in Subarachnoid Hemorrhage (MASH) trial, a ran-
domized, double-blinded, placebo-controlled multicenter
trial with a factorial design. The salicylic acid-related data
were not complete at this stage. A total of 283 patients
were randomized within four days of aneurysmal SAH.
Magnesium treatment consisted of a continuous intrave-
nous dose of 64 mmol/day, begun within four days of
SAH and continued until 14 days after occlusion of the
aneurysm. CT hypointensities (with clinical features of a
decreased consciousness level or new focal neurological
deficit) occurred in 22 of 139 (16%) magnesium-treated
patients and 35 of 144 (24%) placebo-treated patients,
but no data were made available for DCI and delayed cer-
ebral infarction according to the recent consensus paper
[15]. Unfavorable outcomes occurred in 38 of 139 (27%)
magnesium-treated patients and 51 of 144 (35%) pla-
cebo-treated patients. There were no separate outcome
data on excellent outcomes.
In our single-center pilot study [9], 60 patients were
randomly allocated to receive either magnesium sul-
phate infusion (80 mmol/day) or saline infusion for
14 days. We did not record DCI or cerebral infarction
as a separate outcome measure during this pilot study.
A favorable outcome was achieved in 20 of 30 (67%)
patients receiving magnesium sulphate infusion and 16
of 30 (53%) patients receiving the placebo treatment,
and an excellent outcome in 14 of 30 (47%) of the for-
mer and 10 of 30 (33%) of the latter.
Muroi and colleagues [11] reported the results of a
prospective, randomized, patient-blinded, placebo-con-
trolled pilot study of 58 patients with aneurysmal SAH
predominantly treated by microsurgical clipping (97%).
The patients allocated to the treatment group received a
bolus of 16 mmol magnesium sulphate administered
over 15 minutes, followed by a continuous intravenous
infusion of 64 mmol per day for 14 days. To maintain
the serum magnesium level at twice the baseline, with a
maximum of 2.0 mmol/L until the 14th day after SAH,
subsequent dosage adjustments were made every
12 hours. Delayed cerebral infarction occurred in 3 of
31 (10%) patients in the treatment group and 6 of 27
(22%) in the placebo group. A favorable neurological
outcome was achieved in 20 of 31 (64%) patients in the
treatment group and 13 of 27 (48%) in the placebo
group, and an excellent outcome was achieved in 18 of
31 (58%) in the former and 12 of 27 (44%) in the latter.
The Asian-Australasian Intravenous Magnesium Sul-
phate for Aneurysmal Subarachnoid Hemorrhage
(IMASH) trial was a randomized, double-blinded, pla-
cebo-controlled, multicenter phase III trial [12], under
the protocol of which patients who were diagnosed with
acute aneurysmal SAH (within 48 hours of ictus) were
randomly assigned to receive either intravenous magne-
sium sulphate infusion or normal saline infusion (pla-
cebo). For patients receiving the active treatment,
20 mmol of magnesium sulphate was administered over
30 minutes, followed by a continuous infusion of
80 mmol of magnesium sulphate per day for up to 14 days
after the hemorrhage. The plasma magnesium concentra-
tion was measured regularly. The infusion was adjusted to
raise the plasma magnesium concentration to approxi-
mately twice the baseline value and less than 2.5 mmol/L.
The patients in the control group received an equivalent
volume of normal saline. The proportions of patients with
a favorable outcome were similar: 108 of 169 (64%) in the
magnesium sulphate group and 100 of 158 (63%) in the
saline group. So too were those with an excellent outcome:
77 of 169 (46%) in the magnesium sulphate group and 71
of 158 (45%) in the saline group. The proportions of
patients with DCI and delayed cerebral infarction were
also similar.
Westermaier and colleagues [13] recently reported the
results of another single-center, randomized controlled
clinical trial. Patients were randomly allocated to receive
either magnesium sulphate infusion (with a target level of
2.0 to 2.5 mmol/L) or saline infusion for 14 days. This
study reported negative clinical outcomes, but showed a
reduction in DCI and delayed cerebral infarction with
magnesium sulphate infusion. A favorable outcome was
reported for 34 of 54 (63%) patients in the treatment
group and 27 of 53 (51%) in the placebo group, and an
excellent outcome for 27 of 54 (50%) in the former and
18 of 53 (34%) in the latter. DCI occurred in 20 of 53
(37%) patients in the magnesium group and 35 of 53
(66%) in the control group. Delayed cerebral infarction
occurred in 12 of 54 (22%) patients in the magnesium
group and 27 of 53 (51%) in the control group.
Our pilot study [9], IMASH [12], the magnesium
component of the MASH study [8], and the studies pub-
lished by Veyna and colleagues [6], Muroi and collea-
gues [11], and Westermaier and colleagues [13] were
analyzed. The study by Schmid-Elsasser and colleagues
[10] was excluded because of the unconventional omis-
sion of nimodipine in the magnesium group. That by
Pravedello and colleagues [23] was excluded from the
analysis because no measures of DCI, cerebral infarc-
tion, or clinical outcomes were reported. The six eligible
studies were reviewed according to the terminologies
defined in the Methods section (Table 1) The target of
the magnesium arm of the six studies was to produce a
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similar degree of hypermagnesemia, namely, double the
baseline value. All of the studies recruited patients with
SAH during the acute phase, within 48 to 96 hours of
the aneurysmal SAH. The magnesium infusion was
maintained for 10 to 14 days, and the neurological out-
come was measured using the GOS or mRS at three
months [6,8,11] or six months [9,12,13], but not both.
Assessment of risks of bias in included studies
The six eligible studies were assessed for risks of bias
using the Jadad criteria (Table 2). Four of the six trials
were found to have lower bias risks (Jadad score above 3)
[8,9,12,13]. The authors of this systemic review acknowl-
edged potential risk of bias because we were authors of
two of the included studies in this systemic review [9,12].
Meta-analysis of eligible randomized clinical trials with
relevant data available according to the consensus paper
definitions
Two studies with 434 patients were available for analysis
of DCI. The pooled RR for DCI was 0.87 (95% CI =
0.36 to 2.09; P = 0.75; Figure 1). Three studies with 492
patients were available for analysis of delayed cerebral
infarction. The pooled RR for delayed cerebral infarction
was 0.58 (95% CI = 0.35 to 0.97; P = 0.04; Figure 2)
[15].
Three studies with 381 patients and 3 studies with 494
patients were available for analyses of favorable outcome
at three months and six months, respectively. The
pooled RR for a favorable outcome at three months was
1.14 (95% CI = 0.99 to 1.31; P = 0.07; Figure 3), and
that for a favorable outcome at six months was 1.08
(95% CI = 0.94 to 1.24; P = 0.29; Figure 4).
When only the four high-quality randomized clinical
trials (those with a Jadad score above 3) were consid-
ered, two studies with 434 patients were available for
analysis of DCI. The beneficial effect on delayed cerebral
infarction did not persist (RR = 0.61, 95% CI = 0.31 to
1.22; P = 0.17; Figure 5), although the other outcomes
remained statistically similar.
Discussion
The results of our up-to-date meta-analysis suggest that
the present findings do not lend support to a beneficial





























283 Not mentioned No No Yes No No No
Wong 2006
[9]





No Yes Yes Yes No No
Westermaier
2010 [13]
107 Hypocalcemic tetany (1) Yes Yes No No Yes Yes
Wong 2010
[12]
327 Limb weakness (1),
severe electrolyte
disturbance (1)
Yes Yes No No Yes Yes
The terminologies for delayed cerebral ischemia, delayed cerebral infarction, and favorable and excellent outcome are defined in the Materials and methods section.
Table 2 Quality assessment of the randomized controlled clinical trials included




Veyna 2002 [6] Monocenter Not stated Patients were blinded Yes 2
van den Bergh
2005 [30]
Multicenter Study medications were randomized and




Wong 2006 [9] Monocenter Sealed envelopes in order Assessors and health care staff
were blinded
Yes 4
Muroi 2008 [11] Monocenter Not stated Patients were blinded Yes 2
Westermaier
2010 [13]
Monocenter Enveloped lot from a box Assessors were blinded Yes 4
Wong 2010 [12] Multicenter Randomization through Internet/sealed
envelopes in order
Patients, assessors, and health care
staff were blinded
Yes 4
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Figure 1 Random-effects model of risk ratio for delayed cerebral ischemia in aneurysmal subarachnoid hemorrhage patients given
magnesium sulphate infusion and a placebo: a comparison [12,13].
Figure 2 Random-effects model of risk ratio for delayed cerebral infarction in aneurysmal subarachnoid hemorrhage patients given
magnesium sulphate infusion and a placebo: a comparison [11-13].
Figure 3 Fixed-effects model of risk ratio for a favorable outcome at three months: a comparison between magnesium sulphate
infusion and a placebo in patients with aneurysmal subarachnoid hemorrhage [6,11,30].
Figure 4 Fixed-effects model of risk ratio for a favorable outcome at six months: a comparison between magnesium sulphate infusion
and a placebo in patients with aneurysmal subarachnoid hemorrhage [9,12,13].
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effect of magnesium sulphate infusion in reducing DCI
and leading to better clinical outcome. Some would
argue that these negative findings could be due to a lack
of tight neuro-intensive monitoring and treatment,
thereby resulting in variation in management outcomes
and diluting the neuro-protective effects of magnesium
sulphate infusion [24]. However, whether tight para-
meter control, such as glycemic control, would result in
better neurological outcomes remains debatable [24].
The recent meta-analysis by Ma and colleagues sug-
gested that intravenous magnesium therapy reduced the
risk of DCI and poor outcome after aneurysmal SAH
[18]. However, they have not taken into account the
widely varied outcome definitions and time points
among studies and simply pooled for assessments.
Moreover, two more studies had been published since
the meta-analysis by Ma and colleagues. The Asian-
Australasian IMASH study was the first international
multi-center randomized controlled clinical trial in test-
ing the efficacy of intravenous magnesium sulphate infu-
sion in aneurysmal SAH with negative results in all
clinical and surrogate outcomes [12]. Westermaier and
colleagues found a significant 29% decrease in delayed
cerebral infarction and a nonsignificant 9% decrease in
unfavorable outcomes with magnesium sulphate infusion
[13]. However, in the landmark British aneurysm nimo-
dipine trial and recently published IMASH report, the
differences in the proportions of delayed cerebral infarc-
tion paralleled those in the proportions of favorable out-
comes [12,25]. Whether these decreases represent a
change in the pattern of detected delayed cerebral
infarction with the evolution of endovascular treatment
and neuro-intensive care remains to be investigated.
There are several limitations to the meta-analysis pre-
sented in this paper. The regimens of magnesium sul-
phate infusion varied across the different studies, and
caution should thus be exercised in extrapolating the
results. Other problems include the wide variation in the
definitions of outcome measures and the time points of
assessment, making a smaller number of studies available
for meta-analyses of different outcome measures.
Furthermore, there may be a publication bias toward the
reporting of positive trends and spuriously inflated effects
in smaller studies. Statistical heterogeneities were noted
in the meta-analyses for DCI and delayed cerebral infarc-
tion. The risk of bias was assessed with Jadad criteria
[22]; the other option would have been to employ
domain-based evaluation [26]. However, any proposed
tool would have difficulties to validate, and realistic
assessment is eventually open to subjectivity. The recent
consensus is that cerebral infarction on plain computed
tomography (CT) scan is the most objective measure of
DCI, based on the British Aneurysm Nimodipine Trial
and other retrospective analyzes [15,5], in which the data
were obtained primarily from microsurgically treated
intracranial aneurysms. However, identifying delayed cer-
ebral infarction from among all causes of CT hypointen-
sities can be difficult with plain CT alone [27].
Although our post-hoc analysis of the IMASH data did
not suggest a higher achieved plasma magnesium con-
centration to be associated with a better clinical outcome
[28], the current evidence suggests that the development
of a clinical trial targeting reductions in symptomatic
vasospasm and cerebral infarction, and an improvement
in clinical outcomes, would require a large sample size
(as many as 2,445 patients) to demonstrate the efficacy of
such treatment in improving neurological outcomes,
even with a treatment effect size of 50% [29]. Finally, the
relatively small number of patients in the present meta-
analysis could mask a possible smaller beneficial effect of
magnesium sulphate infusion. Another European multi-
center trial (Magnesium in Aneurysmal Subarachnoid
Hemorrhage: MASH II) employing a slightly lower
dosage regimen is ongoing and should contribute further
data for future meta-analysis of the use of magnesium
sulphate infusion in patients with aneurysmal SAH [30].
Conclusions
The reduction in DCI and improvement in clinical out-
comes for aneurysmal SAH patients with magnesium
Figure 5 Random-effects model of risk ratio for delayed cerebral infarction: a comparison between magnesium sulphate infusion and
a placebo in patients with aneurysmal subarachnoid hemorrhage (trials with a Jadad score above 3 included) [12,13].
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sulphate infusion observed in previous pilot studies has
not been confirmed although a beneficial effect cannot
be ruled out because of sample size limitation.
Key messages
• Pilot studies have suggested the possible beneficial
effects of magnesium sulphate infusion in treating
patients with aneurysmal SAH, but previous meta-
analyses have become outdated by recently published
clinical trials.
• An up-to-date systemic review and meta-analysis
showed that magnesium sulphate infusion does not
reduce DCI or improve neurological outcomes
although a beneficial effect cannot be ruled out
because of sample size limitation.
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